160 Parallel studies in humans could help form the rational basis for a more unified PD-L1 immunohistochemistry scoring approach. In conclusion, the recent success of immune-based cancer therapy ...

From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.

During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Scot Niglio discussing two abstracts: “Safety and efficacy of neoadjuvant immunotherapy with ...

Epithelioid vascular tumors, including epithelioid hemangiomas and osteoblastomas, represent a unique category of neoplasms characterized by their distinct cellular features and genetic profiles.

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...